Biopharma Daily Stock Updates - 05/19/22

Table of Contents:

$AKTX +7.6% Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting source

$MRTX -6.8% Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer source

$FHTX -25.8% Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS source

$ACRX +27.6% AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® source

$TCDA +4.0% Tricida Announces Administrative Stop of the VALOR-CKD Trial source

$CALT +18.0% Calliditas receives positive CHMP opinion in IgA nephropathy source

$CLBS +1.0% Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease source

$SIGA +17.1% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) source

$MRSN +4.9% Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer source

$ALRN +0.7% Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer source

$RCKT +0.5% Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) source

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

$

Posted by JM